INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hims & Hers Health, Inc.

Hims & Hers shares dropped sharply after regulatory and billing/privacy scrutiny: on July 29, 2026 the stock fell $4.32 (-14.73%) to $25.00 following an FTC lawsuit alleging sharing customers’ medical information with third-party advertisers. On August 24, 2026, shares fell $2.70 (-7.99%) to $31.08 after Bloomberg reported Visa put Hims on notice for excessive complaints, with each disputed transaction carrying an $8 surcharge and an estimated nearly $75,000 bill due in September. Pomerantz is also investigating potential securities fraud or unlawful practices, adding further downside risk.

Analysis

The core issue is not the dollar cost of either action; it is that HIMS is now facing a layered trust-tax across acquisition, retention, and payments. When a subscription brand gets pushed into higher dispute monitoring, the hidden cost is usually a mix of reserve requirements, processor friction, and lower ad efficiency as platforms tighten sensitive-category policies. That can compress both gross margin and valuation multiple because the market stops underwriting the business as a clean DTC growth story and starts treating it like a compliance-heavy consumer lender.

Second-order, the pressure should spill into any telehealth model that relies on aggressive paid acquisition plus recurring billing. If complaint ratios remain elevated, the likely response is less spend on the very channels that produce the cheapest growth, which can slow new-customer adds before it shows up in revenue. For META and SNAP, the immediate P&L impact looks limited, but the broader implication is that regulated-health advertisers may face more restrictive targeting and higher review burdens; that is more of a policy headline risk than an earnings risk unless discovery proves the data-sharing issue was systemic.

Visa is the cleanest relative winner because the direct economic hit is trivial, and the platform can simply push merchant underwriting costs back onto the merchant. The real falsifier for the bearish HIMS view is not a legal dismissal; it is evidence that disputes normalize and no material reserve or processing change appears by next earnings. Absent that, the stock likely trades with a persistent litigation/operational discount over the next 1-3 months, with structural multiple pressure lasting 6-18 months if consumer-trust metrics deteriorate further.

Key Decisions for Investors

• Short HIMS on any bounce toward $32-$34; target a move back into the high-$20s over 1-3 months. Stop the trade if management shows dispute rates, chargebacks, and cancellations have normalized and no reserve/processor actions are taken.
• Use HIMS 1-3 month put spreads rather than naked shorts if borrow/vol becomes expensive; structure for a 2:1 to 3:1 payoff with downside into the next earnings window.
• Relative-value: long V / short HIMS. The idea is not that Visa gains materially, but that HIMS bears the real underwriting and trust risk while V should remain insulated unless chargebacks broaden across merchants.
• Do not chase META or SNAP on this headline alone; keep them on watch for any evidence in upcoming disclosures that regulated health advertisers are being pushed out of performance channels. Only act if ad revenue commentary weakens or privacy scrutiny expands.
• Set a catalyst alert on HIMS next earnings for dispute ratios, merchant reserve language, cancellation metrics, and customer acquisition cost. If any of those worsen, the thesis is confirmed; if all stabilize, cover aggressively.